Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors. While some patients achieved prolonged progression-free survival, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial and impacted long-term tolerability.
Authors
- Xiaobu Ye (ORCID: https://orcid.org/0009-0005-5356-4840)
- Stuart A. Grossman (ORCID: https://orcid.org/0000-0002-3726-7679)
- Arati Desai (ORCID: https://orcid.org/0000-0002-4849-4703)
- David Schiff
- Benjamin M. Ellingson (ORCID: https://orcid.org/0000-0002-2764-6640)
- Tobias Walbert (ORCID: https://orcid.org/0000-0003-0667-8106)
- Antonio M. P. Omuro (ORCID: https://orcid.org/0000-0003-4299-3664)
- Jian Campian (ORCID: https://orcid.org/0000-0002-5317-8481)
- Ranjit S. Bindra (ORCID: https://orcid.org/0000-0002-3255-0467)
- Neeraja Danda (ORCID: https://orcid.org/0009-0003-1168-0742)
- Patrick Y Wen (ORCID: https://orcid.org/0000-0002-2452-0540)
- Byram H. Ozer
- Burt Nabors (ORCID: https://orcid.org/0000-0001-5926-2230)
- Serena Desideri
- Jing Li (ORCID: https://orcid.org/0000-0001-8669-4901)
Institutions
- Yale New Haven Hospital (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Wayne State University (US)
- Washington University in St. Louis (US)
- Johns Hopkins Medicine (US)
- Henry Ford Hospital (US)
- University of Alabama at Birmingham (US)
- Yale University (US)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Yale New Haven Health System (US)
- University of Virginia (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1093/neuonc/noaf246
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05